43 new PD patients. They were then followed prospectively for the development of cardiovascular events. All-cause mortality and duration of hospitalization for cardiovascular diseases were also recorded. ♦♦ ♦♦ ♦ Result: The average duration of follow-up was 26.5 ± 17.6 months. During the follow-up period, 15 patients developed cardiovascular events. Event-free survival at 36 months was 81.4% and 53.6% for low (<300 mg/L) and high (≥≥ ≥≥ ≥300 mg/L) peritoneal albumin excretion groups respectively (log rank test, p = 0.042). By Cox regression analysis, the only independent factors for event-free survival were diabetic status and peritoneal albumin excretion rate. For every 100 mg/L increase in peritoneal albumin excretion, the adjusted hazard ratio of developing a cardiovascular event was 1.83 [95% confidence interval (CI) 1.11 -3.02, p = 0.018]. Actuarial patient survival at 36 months was 85.7% and 59.1% for low and high peritoneal albumin excretion groups respectively (log rank test, p = 0.10). After adjusting for the duration of follow-up for individual patients, the average duration of hospitalization was 9.1 ± 16.2 and 21.7 ± 25.7 days per year of follow-up for low and high peritoneal albumin excretion groups respectively (Mann-Whitney U test, p = 0.012). ♦♦ ♦♦ ♦ Conclusion: Although the sample size of our present study is small and does not have adequate statistical power, we conclude that peritoneal albumin excretion may be an important predictor of cardiovascular disease. Further studies are needed to examine the role of dialysate albumin excretion as a means of cardiovascular risk stratification in PD patients.
I
t is now recognized that inflammation plays a pivotal role in the pathogenesis of atherosclerotic disease and malnutrition (1, 2) . An elevated plasma C-reactive protein (CRP) level, which is induced by other proinflammatory cytokines, is associated with risk of myocardial infarction (3) and mortality (4) in peritoneal dialysis (PD) patients. On the other hand, proinflammatory cytokines can cause protein catabolism and malnutrition (5) (6) (7) . Several studies found that inflammation, alone or in combination with low protein intake, causes hypoalbuminemia in dialysis patients (8, 9) . The complicated interactions between malnutrition, inflammation, and atherosclerotic diseases are now known as the "MIA syndrome" (10) . It is the current hypothesis that systemic inflammation is tightly linked to the most common complications of renal patients, in particular those
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It is generally believed that inflammation causes vascular diseases by inducing endothelial dysfunction, which, at least in nonuremic patients, has important roles in the pathogenesis of atherosclerosis (12) . Endothelial dysfunction can be measured with a panel of serum markers (13) (14) (15) , but all are expensive and none is applicable for routine clinical use. Interestingly, microalbuminuria potentially represents a simple and inexpensive marker of endothelial dysfunction (16) . The relationship between microalbuminuria and cardiovascular disease (CVD) was first noted in diabetic patients (17) , but has since been documented in nondiabetic populations (18, 19) . Although the exact nature of this association is not fully understood, it has been proposed that microalbuminuria represents a systemic endothelial abnormality (16), affecting not only glomerular capillaries but also arterial and arteriolar intimal function, thereby promoting transvascular escape of atherogenic molecules (20) .
If microalbuminuria is a result of systemic endothelial dysfunction, we predict that peritoneal albumin loss in PD patients, which is conceptually analogous to microalbuminuria in nonuremic patients, would also be a surrogate marker of endothelial dysfunction and a predictor of CVD in PD patients. We have previously reported that patients with preexisting CVD prior to initiation of dialysis had marginally higher levels of dialysate albumin and total protein excretion, indicating that dialysate protein loss is a cardiovascular risk marker (21) . Here we report a prospective study examining the relationship between peritoneal protein loss and vascular disease in a cohort of new PD patients.
PATIENTS AND METHODS

PATIENT SELECTION
As described in our previous cross-sectional study, we recruited 43 consecutive new PD patients (21) . A standard peritoneal permeability test (PET) (22) was performed within 2 months after the commencement of PD, when the patient was in a euvolemic state. On the day prior to the PET, 24-hour urine and dialysate collection was performed for assessment of nutritional status. Presence of diabetes and history of CVD at initiation of dialysis were recorded. Cardiovascular disease was defined as angina, class III -IV congestive heart failure, a history of myocardial infarction, cerebrovascular accident, or amputation due to vascular disease.
STUDY OF PERITONEAL TRANSPORT
The standard PET was performed by the method of Twardowski et al. (22) . Briefly, a 4-hour dwell study was carried out with 2 L 2.5% dextrose dialysis fluid (Dianeal; Baxter-Travenol, Deerfield, Illinois, USA). Dialysate creatinine and glucose levels at 0, 2, and 4 hours, and plasma creatinine and glucose levels at 2 hours were measured. Drainage and ultrafiltration volumes at 4 hours were documented. Dialysate-to-plasma ratios of (D/P) creatinine at 0, 2, and 4 hours were calculated after correction for glucose interference. The results were plotted on a PET graph. Patients were classified as high, high average, low average, and low transporters as described by Twardowski (22) . Mass transfer area coefficients of creatinine normalized for body surface area were calculated using the formula described by Krediet et al. (23) . Body surface area was determined by nomogram using body weight and height (24) .
PERITONEAL PROTEIN AND ALBUMIN EXCRETION RATES
During the PET, dialysate albumin and total protein concentrations at 4 hours were determined using a fully automated analyzer (Konelab 60; Thermo Clinical Labsystems, Espoo, Finland); the concentrations were adjusted for the dialysate creatinine concentration. In all measurements, creatinine concentration in dialysate was corrected for glucose interference according to a formula provided by our laboratory (25) .
MARKERS OF NUTRITION AND INFLAMMATION
On the day prior to the PET, 24-hour urine and dialysate collection was performed. Lean body mass was calculated according to the formula described by Forbes and Bruining (26) and normalized to percentage by ideal body weight, which was determined by body height and sex according to a standard formula validated in southern Chinese subjects (27) . Protein catabolic rate was calculated using the modified Bergström formula (28) . Daily protein loss in dialysate was measured using a standard biochemical method. Serum albumin was measured by bromcresol purple method. Serum CRP was measured by the Tina-quant CRP (latex) ultrasensitive assay (Roche Diagnostics GmbH, Mannheim, Germany).
B-MODE CAROTID DOPPLER EXAMINATION
In 25 patients, Doppler ultrasonographic examinations were performed using an HDI 5000 ultrasound scanner [ATL (Advanced Technology Laboratories), Bothell, Washington, USA]. A trained sonographer scanned the right and left common carotid arteries, the carotid bulbs, and the first 2 cm of the internal and external carotid arteries. For each location, the sonographer visualized the vessel in multiple planes and then focused on the interfaces required to measure intimamedia thickness (IMT), as well as any areas of calcified or ulcerated plaque. Carotid plaque was defined as echogenic structures showing protrusion into the lumen, with focal widening 50% greater than the IMT of adjacent sites. All measurements were performed by a technician who was blinded to the patients' clinical details and laboratory results.
CLINICAL FOLLOW-UP
All patients were to be followed for at least 3 years. Clinical management and dialysis regimen were decided by individual nephrologists and were not affected by the study. Clearance studies were performed in all patients by standard methods, as described above, at least yearly. Primary end point was a composite one that consisted of cardiovascular death, nonfatal myocardial infarction or stroke, hospital admission for unstable angina, coronary intervention, transient ischemic attack, or lower limb ischemia. Secondary end points included duration of hospitalization (all-cause), cardiovascular mortality, and all-cause mortality. Censoring events for survival analysis included transfer to long-term hemodialysis, kidney transplant, recovery of renal function, loss to follow-up, and transfer to other dialysis centers.
STATISTICAL ANALYSIS
Statistical analysis was performed using SPSS for Windows software, version 11.0 (SPSS Inc., Chicago, Illinois, USA). Results are expressed as mean ± SD unless otherwise specif ied. Comparisons between groups were performed by chi-square test, Student's t-test, or KruskalWallis test, as appropriate. Factors independently associated with peritoneal albumin excretion rate were explored by multiple linear regression model, with backward stepwise analysis. For convenience of analysis, we further divided the patients into those with "low" (<300 mg/L) and those with "high" (≥300 mg/L) peritoneal albumin excretion, the cutoff of which was approximately the median peritoneal albumin excretion in our patients. Cox proportional hazard model was used for statistical analysis of peritoneal albumin excretion rate on the composite cardiovascular end point as well as actuarial patient survival (29) . For survival analysis, all patients who remained alive and on PD at the end of the study were administratively censored on 31 December 2003. In addition to peritoneal albumin excretion, the Cox models were constructed by patient age, diabetic status, preexisting CVD, baseline serum CRP, peritoneal transport group, total Kt/V, and residual renal function. These parameters were selected for the construction of the Cox model because of their importance in determining patient survival, according to previous studies.
Because the data on hospitalization were highly skewed, they were corrected for the duration of followup and then compared using the Mann-Whitney U test. The number and duration of hospital admissions were further compared between groups by analysis of covariance (ANCOVA). In this analysis, hospitalization data were used as dependent variables (after correction for the duration of follow-up and log transformation because the data were highly skewed), peritoneal albumin excretion was used as grouping factor, and patient age, diabetic status, preexisting CVD, baseline serum CRP, serum albumin, peritoneal transport group, total Kt/V, and residual renal function as the covariates. A p value of less than 0.05 was considered significant. All probabilities were two tailed.
RESULTS
We enrolled 43 new PD patients. Their baseline demographic and clinical characteristics have been described in our previous report (21) and are summarized in Table 1 . The average duration of follow-up was 26.5 ± 17.6 months (some patients died or changed to another treatment modality), with a total follow-up period of 1139 patient-months. The average peritoneal albumin excretion rate was 310.8 ± 126.6 mg/L. For convenience of analysis, patients were divided into those with "low" (<300 mg/L) and those with "high" (≥300 mg/L) peritoneal albumin excretion and their baseline cardiovascular risk factors were compared, as summarized in Table 2 . The high albumin excretion group had more diabetic patients and marginally higher serum CRP, and was slightly older than the low albumin excretion group. Peritoneal albumin excretion correlated with serum CRP level (r = 0.330, p = 0.03), a marker of systemic inflammation, but not serum albumin level (r = -0.211, p = 0.2). Dialysate albumin level closely correlated with D/P creatinine at 4 hours (Pearson's r = 0.601, p < 0.001). Patients with calcified or ulcerated carotid atherosclerotic plaques had marginally higher peritoneal albumin excretion than those without (406.6 ± 177.6 vs 268.4 ± 62.6 mg/L, p = 0.07), although the result was not statistically significant. Multiple linear regression models showed that peritoneal albumin excretion was independently associated with diabetes, preexisting CVD, peritoneal transport of small solutes (represented by D/P creatinine at 4 hours of the PET), body weight, and proteinuria (Table 3) .
CARDIOVASCULAR EVENTS
During the study period, 15 patients developed cardiovascular events. These included fatal myocardial infarction (8 cases), nonfatal myocardial infarction or acute coronary syndrome (4 cases), and cerebrovascular accident (3 cases). Event-free survival by Kaplan-Meier plot, dividing patients into those with high and those with low peritoneal albumin excretion, showed a marked difference ( Figure 1 ). Event-free survival at 36 months was 81.4% and 53.6% for low and high peritoneal albumin excretion groups respectively (log rank test, p = 0.042).
Results of Cox proportional hazard model for eventfree survival are summarized in Table 4 . In multivariate analyses, independent factors for event-free survival were diabetic status and peritoneal albumin excretion rate. In this model, for every 100 mg/L increase in peritoneal albumin excretion, the adjusted hazard ratio of developing the composite end point was 1.83 [95% confidence interval (CI), 1.11 -3.02, p = 0.018]. It could 
ALL-CAUSE MORTALITY
During the study period there were 15 deaths. The causes of death were myocardial infarction (8 cases), peritonitis (4 cases), non-peritonitis infection (2 cases), and perforated colon (1 case). During the same period there were 9 transplants, 5 patients changed to hemodialysis, and 1 patient recovered renal function. Actuarial patient survival at 36 months was 85.7% and 59.1% for low and high peritoneal albumin excretion groups respectively (log rank test, p = 0.101). By multivariate analysis with the Cox proportional hazard model, the only independent factor for actuarial survival was diabetic status, with adjusted hazard ratio of 5.81 (95% CI, 1.70 -19.83, p = 0.005). In this model, for every 100 mg/L increase in peritoneal albumin excretion, the adjusted hazard ratio of all-cause mortality was 1.49 (95% CI, 0.91 -2.73, p = 0.09), which fell short of statistical significance.
HOSPITALIZATION FOR CVD
There were 1067 days of hospitalization for CVD during the study period. Eight patients (18.6%) were never hospitalized during the study period. After adjusting for the duration of follow-up for individual patients, the average durations of hospitalization were 9.1 ± 16.2 and 21.7 ± 25.7 days per year of follow-up for the low and high peritoneal albumin excretion groups respectively (Mann-Whitney U test, p = 0.012) (Figure 2 ). After adjusting for age, diabetic status, preexisting CVD, baseline serum CRP, serum albumin, peritoneal transport status, total Kt/V, and residual renal function, the difference in hospitalization between peritoneal albumin excretion groups remained statistically significant (p = 0.02). In this model, expected hospitalization for the low peritoneal albumin excretion group was 2.4 (95% CI, 0.4 -6.9) days per year, and for the high peritoneal albumin excretion group 12.7 (95% CI, 6.5 -20.5) days per year. By the same model, diabetes (p = 0.037) and residual renal function (p = 0.026) were the only other independent factors for the duration of hospitalization.
DISCUSSION
Traditionally, high peritoneal transporters are believed to be prone to fluid retention and peritoneal protein loss, which result in malnutrition and patient morbidity (30) . However, recent studies show that the association between peritoneal transport status and malnutrition exists before patients are actually started on PD (31, 32) . In our previous cross-sectional study, we found that patients with preexisting CVD prior to initiation of dialysis have higher peritoneal albumin excretion (21) , indicating that dialysate albumin excretion is a marker of underlying vascular disease rather than the cause of chronic fluid overload. Our present prospective study further extends the observation and confirms that peritoneal albumin excretion is a strong predictor of CVD. The effect is independent of other confounding factors, notably preexisting CVD and serum CRP. Because of limitations in the original study design, we could not ascertain that peritoneal albumin excretion rate is directly related to endothelial dysfunction or systemic inflammation. In fact, the univariate association of CRP with peritoneal albumin excretion revealed only 33% correlation, suggesting only a modest contribution of underlying inflammation to peritoneal albumin loss. Nevertheless, peritoneal albumin excretion was associated with the extent of calcified and ulcerated carotid atherosclerotic plaques by Doppler ultrasound, indirectly supporting the relation with endothelial dysfunction. The result of the present study also agrees with our previous observation that hyaluronan level in PD effluent is an independent predictor of patient survival (33). In retrospect, hyaluronan level in PD effluent is probably another marker of peritoneal permeability to macromolecules. Taken together, the available evidence is consistent with the hypothesis that peritoneal permeability to albumin, and possibly to other macromolecules, is a surrogate marker of systemic endothelial dysfunction. This hypothesis provides an alternative explanation for the association between peritoneal transport status and the morbidity of PD patients (30, 31) .
Our findings may provide new insight in the search for a biochemical marker for CVD. Contrary to other sophisticated serum markers of endothelial dysfunction [e.g., serum intercellular adhesion molecule-1, vascular cell adhesion molecule-1 (13-15)], peritoneal albumin excretion can be determined by the same assay for screening of diabetic microalbuminuria, which is available in most hospital laboratories. We believe dialysate albumin excretion may provide a simple and convenient measure of endothelial dysfunction in PD patients. The assay is widely available and measurements can be easily incorporated into the standard PET, which is generally recommended for all new PD patients.
It is important to note that our present study has a small sample size and a very low event rate, resulting in inadequate statistical power. For example, we did not observe significant effects of age, total Kt/V, or residual renal function, all major predictors of patient survival (34, 35) . In addition, only baseline values of CRP, Kt/V, and residual renal function and not their follow-up data are used for statistical modeling, which further limits statistical power. Nevertheless, a single time point CRP has been found to be predictive of outcome in PD patients (36) . The small sample size probably also explains the paradoxical finding that a high peritoneal albumin excretion rate but not preexisting CVD predicted the primary outcome. Our result does not prove that peritoneal albumin loss exerts a greater prognostic impact on cardiovascular risk than established atherosclerotic disease. Further large-scale study is needed to define the role of dialysate albumin excretion as a means of cardiovascular risk stratification in PD patients. Power estimation by the Power Analysis and Sample Size for Windows software (PASS 2000; NCSS, Kaysville, Utah, USA), with two-sided log rank test, shows that, to achieve 80% power at a 0.05 significance level to detect the difference in survival, an overall sample size of 129 subjects is required.
In the present study, peritoneal albumin excretion was measured only once at the beginning of the study period because of practical constraint. However, experience from other biochemical parameters suggests that a single measurement may be biased (37, 38) . To our knowledge, there are no published data on the longitudinal change in peritoneal albumin excretion with time on dialysis. Several groups have showed that longitudinal change in peritoneal permeability to small solutes (usually urea and creatinine) follows a centripetal pattern (39, 40) . It is possible that, with prolonged use of bioincompatible PD solution and repeated peritonitis, peritoneal albumin excretion rate may change with time on dialysis, independent of the presence of systemic endothelial dysfunction. On the other hand, KaplanMeier plot of the composite cardiovascular end point shows that the majority of cardiac events in patients with high peritoneal albumin excretion occurred within 12 months (see Figure 1) , suggesting that peritoneal albumin excretion is a short-term marker of cardiovascular or endothelial instability. Serial measurements may therefore be valuable for monitoring the progress of endothelial dysfunction; however, this hypothesis has not been addressed by our present study.
